Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Infectious Disease Research Institute
DescriptionRecombinant vaccine comprising two fused Leishmania proteins plus GLA-SE adjuvant
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationLeishmaniasis
Indication DetailsPrevent visceral leishmaniasis (VL)
Regulatory Designation
PartnerEmcure Pharmaceuticals Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today